Summary
Tuftsin, a physiological tetrapeptide derived from the Fc region of leukophilic IgG possesses a variety of immunopotentiating properties including the ability to act as an immunotherapeutic agent against the experimental tumors, L 1210 leukemia and Cloudman S-91 melanoma. Although the mechanism of action of tuftsin in vivo is not known, several types of leukocytes have been shown to become cytotoxic effector cells following activation with tuftsin. These cells presently include macrophages, natural killer cells, and granulocytes. The possibility that tuftsin can also activate other types of effector cells have not been ruled out. We feel this small peptide has a high potential (largely unrecognized) as an antitumor immunopotentiating agent. It is naturally occurring in man and appears to be relatively non-toxic. Its exact sequence (Thr-lys-Pro-Arg) is known and it can be chemically synthesized. Methods are also available to monitor the levels of tuftsin in body fluids. These properties along with its ability to control infectious disease make this agent one of the more promising immunopotentiators.
Similar content being viewed by others
References
Nishioka, K., Constantopoulos, A., Satoh, P. S. & Najjar, V. A., 1972. Biochem. Biophys. Res. Commun. 47: 172–179.
Constantopoulos, A. & Najjar, V. S., 1972. Cytobios 6: 97–100.
Nishioka, K., Constantopoulos, A., Satoh, P. S., Mitchell, W. M. & Najjar, V. A., 1973. Biochim. Biophys. Acta 310: 217–229.
Nishioka, K., Satoh, P. S., Constantopoulos, A. & Najjar, V. A., 1973. Biochim. Biophys. Acta 310: 230–237.
Nishioka, K., 1978. Gann 69: 569–572.
James, K., McBride, B. & Stuart, A., 1977. The Macrophage and Cancer. University of Edinburgh, Edinburgh.
Klebanoff, S. J. & Clark, R. A., 1978. The Neutrophil: Function and Clinical Disorders. North-Holland Publishing Co., New York.
Stabinsky, Y., Gottlieb, P., Zakuth, V., Spirer, Z. & Fridkin, M., 1978. Biochem. Biophys. Res. Commun. 83: 599–606.
Nair, R. M. G., Ponce, B. & Fudenberg, H. H., 1978. Immunochem. 15: 901–907.
Bar-shavit, Z., Stabinsky, Y., Fridkin, M. & Goldman, R., 1979. J. Cell. Physiol. 100: 55–62.
Kiessling, R. & Wigzell, H., 1979. Immunol. Rev. 44: 1-5-208.
Anderson, R., Glover, A., Koornhof, H. J. & Rabson, A. R., 1976. J. Immunol. 117: 428–432.
Scheetz, M. E. II, Thomas, L. J., Allemenos, D. K. & Schinitsky, M. R., 1976. Immunol. Commun. 5: 189–203.
Poplack, D. G., Sher, N. A., Chaparas, S. D. & Blaese, R. M., 1976. Cancer Res. 36: 1233–1237.
Nishioka, K., 1979. Br. J. Cancer 39: 342–345.
Takami, H. & Nishioka, K., 1980. Br. J. Cancer. In press.
Nishioka, K., Romsdahl, M. M., Fritsche, H. A. Jr. & McMurtrey, M. J., 1977. Int. J. Cancer 20: 689–693.
Noyes, R. D., Babcock, G. F. & Nishioka, K., 1980. Proc. Am. Assoc. Cancer Res. 21: 261.
Bruley-Rosset, M., Hercend, T., Florentin, I. & Mathé, G., 1980. Proc. Am. Assoc. Cancer Res. 21: 250.
Florentin, I., Bruley-Rosset, M., Kiger, N., Imback, J. L., Winternitz, F. & Mathé, G., 1978. Cancer Immunol. Immunother. 5: 211–216.
Babcock, G. F., Phillips, J. H. & Nishioka, K., 1980. 4th Int. Congress Immunol. In press.
Reppun, T., Lin, S. & Kuhn, C., 1979. J. Reticuloendothel. Soc. 25: 379–386.
Nishioka, K., 1979. Gann 70: 845–846.
Tzehoval, E., Segal, S., Stabinsky, Y., Fridkin, M., Spirer, Z. & Feldman, M., 1978. Proc. Natl. Acad. Sci. USA 75: 3400–3404.
Boumsell, L. & Meltzer, M. S., 1976. J. Immunol. 115: 1746–1748.
Kent, H. A., 1974. Biol. Reprod. 12:504–507.
Friedman, R. M., 1978. J. Natl. Cancer Inst. 60: 1191–1194.
Becker, E. L. & Showell, H. J., 1974. J. Immunol. 112: 2055–2062.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nishioka, K., Babcock, G.F., Phillips, J.H. et al. Antitumor effect of tuftsin. Mol Cell Biochem 41, 13–18 (1981). https://doi.org/10.1007/BF00225293
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00225293